Download Japanese Cancer Association Japanese Cancer Associati

apanese
JCancer
Association
http://www.jca.gr.jp
Executive Office
International Medical Information Center
Shinanomachi Rengakan, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-0016, Japan
Telephone: +81-3-5361-7156 (Direct) FAX: +81-3-3358-1633
E-mail: [email protected]
Be part of JCA member:
A place for knowledge exchange and networking
02
75th Annual Meeting in
01
President Kohei Miyazono
Message from JCA
“Breakthroughs in Cancer
Treatment: Collaboration of Basic,
Translational and Clinical Research”
“Conquering cancer through research” is
our ultimate mission of the Japanese Cancer
Association JCA, and this has also been a topic
at our recent annual meetings. Nevertheless,
how to direct basic research in cancer towards
applications in clinical practice has been a key
issue in cancer research, with the focus on linking
basic research with clinical practice. This has no
doubt been driving the developments in cancer
research in recent years. In light of this, we hope
to create a program for the 75th Annual Meeting
of JCA that will consider cancer research from the
perspective of how we can best facilitate so-called
“breakthroughs” in research, which will lead to
innovative diagnostic and treatment methods.
Tyrosine-kinase inhibitors and immunotherapy
are examples of targeted molecular therapies
that have been developed over the past few
years. These therapies originated from basic
research that initially did not necessarily have
any association with cancer. Decades of research
have produced more than a few research findings
with the potential for clinical application. In order
to transfer these findings into clinical practice,
it is imperative to promote interdisciplinary
research comprising a wide range of specialists
in medicine, life science, pharmaceutical science,
and other fields. Another distinguishing feature
of cancer research is that findings in other fields
outside medicine and life science can also lead to
the development of new therapies and diagnostic
devices. The integration of cancer research
with other fields is a key factor in achieving the
breakthroughs we are seeking.
In addition to discussing this theme, we would
like the 75th Annual Meeting of JCA to be
an opportunity for considering how we can
recruit and train young cancer researchers, as
well as looking at effective ways to make our
internationalized association even more global in
its reach.
We look forward to receiving your valued
opinions and suggestions, so that we can ensure
the 75th Annual Meeting of JCA is a meaningful
and worthwhile opportunity for all attendees.
Kohei Miyazono
President
The 75th Annual Meeting
of the Japanese Cancer
Association
05
International Sessions (IS)
One of our most important missions is to stimulate
international scientific exchange and collaboration. Towards
this goal, we organize several International Sessions
(IS) throughout the three-day annual meeting. Twelve
hot topics will be selected each year, and two IS will be
held each morning and afternoon during the conference.
Prominent researchers in the fields of the topics will be
invited both from Japan and from overseas. In addition,
a few presentations will be selected for IS from general
attendants, as stand-alone talks, targeting in particular
young researchers. Because all talks and discussions will be
given in English, IS will provide an excellent opportunity to
become acquainted with scientists from all over the world.
Young Scientists Award 2015
AACR-JCA Joint Conference
in Hawaii
The AACR-JCA Joint Conference has been held every
three years since 1989, with changing venues in the
Hawaiian islands. The 10th Joint Conference was held in
Maui, Hawaii, in February 2016, co-chaired by Dr. Frank
McCormick (UCSF Helen Diller Family Comprehensive
Cancer Center, CA, USA) and Dr. Tetsuo Noda (Japanese
Foundation for Cancer Research, Tokyo, Japan) under
the title of “Breakthroughs in Cancer Research: From
Biology to Therapeutics”. About 570 participants attended
the conference. Keynote lectures were presented on the
first day by Dr. Suzanne L. Topalian (Johns Hopkins
Kimmel Comprehensive Cancer Center, MD, USA) and
Dr. Yusuke Nakamura (The University of Chicago, IL,
USA). After the keynote lectures, 37 talks and more than
300 posters were presented. Participants had fruitful
discussions during the conference, and enjoyed their
stay in Hawaii. The next AACR-JCA Joint Conference,
scheduled in February 2019,
will be organized by Dr. Hitoshi
Nakagama (National Cancer
Center Research Institute,
Tokyo, Japan) and a cochairperson from AACR.
Year
Title
C h a ir p e r so n s
10th (2016)
Breakthroughs in Cancer Research:
From Biology to Therapeutics
Tetsuo Noda (JFCR)
Frank McCormick (UCSF)
9th (2013)
Breakthroughs in Basic and
Translational Cancer Research
Kohei Miyazono (Univ. of Tokyo)
Tyler Jacks (Mass. Inst. Tech)
8th (2010)
Cancer Genomics, Epigenomics, and the
Development of Novel Therapeutics
Yusuke Nakamura (Univ. of Tokyo)
Peter A Jones (Univ. of Southern California)
7th (2007)
In the Forefront of Basic and
Translational Cancer Research
Kohzoh Imai (Sapporo Medical Univ.)
Lynn M. Matrisian (Vanderbilt Univ.)
6th (2004)
Advances in Cancer Research:
Molecular and Cellular Biology,
Genomics and Proteomics, Targeted
therapeutics, Novel Clinical Trials,
Molecular and Genetic, Epidemiology /
Prevention
Takashi Tsuruo (Univ. of Tokyo)
Waun Ki Hong (UT M. D. Anderson Cancer Center)
5th (2001)
Molecular Biology and New
Therapeutic Strategies: Cancer Research
in the 21st Century
Setsuo Hirohashi (NCCRI)
Webster K. Cavenee (Univ. of California at San
Diego)
4th (1998)
Innovative Approaches to the
Prevention, Diagnosis, and Therapy of
Cancer
Kaoru Abe (NCC)
Edward Bresnick (Univ. of Mass. Med. Ctr.)
3rd (1995)
Molecular Biology of Cancer:
Implications for Prevention and
Therapy
Masaaki Terada (NCCRI)
Lee W. Wattenberg (Univ. of Minnesota)
2nd (1992)
Molecular Oncology as a Basis for New
Strategies in Cancer Therapy
Susumu Nishimura (NCC Research Institute; NCCRI)
I. Bernard Weinstein (Columbia Univ.)
1st (1989)
Molecular Aspects of Growth Control
Takashi Sugimura (National Cancer Center; NCC)
Enrico Mihich (Roswell Park Memorial Inst.)
10th Chairperson
Tetsuo Noda
04
Timothy C. Wang,
Columbia University
Medical Center
JCA-AACR
Special Joint
Conference
The 4th JCA-AACR Special Joint Conference,
sponsored by the JCA and AACR, was
focused on “The Latest Advances in Gastric
Cancer Research: From Basic Science to
Therapeutics”. It was held December 16-18,
2013 at the Tokyo Bay Maihama Hotel Club &
Resorts, and was perhaps the most successful
Special Joint Conference yet. The conference
was organized by three JCA committee
members (Drs. Masanori Hatakeyama,
Atsushi Ohtsu, Wataru Yasui) and three AACR
committee members (Drs. Timothy C. Wang,
James G. Fox and James R. Goldenring).
There were 172 participants from 8 different
countries, and the program including 27
invited talks and 99 posters. The next JCAAACR Special Joint Conference, scheduled on
July 13-15, 2016 at the Tokyo Bay Maihama
Hotel Club & Resorts, will be focused on
hematological cancer research. The conference
will be organized by three JCA committee
members (Drs. Takuro Nakamura, Issay
Kitabayashi, Shigeru Chiba) and three AACR
committee members (Drs. Jonathan D. Licht,
Ross L. Levine, Catriona H. M. Jamieson).
The meeting will focus on the following
topics: leukemic stem cells and metabolism,
ageing and epigenetics, genetic alterations
of leukemia, myeloproliferative neoplasms/
myelodysplastic syndrome, novel therapeutics
of lymphoma and multiple myeloma, and
immunotherapy of hematopoietic neoplasms.
Open Free
access!
Cancer Science is a fully peer reviewed open access journal.
The journal averages only 17 days
from submission to first decision, providing high quality rapid publication
of cutting-edge research.
Submit your paper to the most cited
cancer journal from Asia.
The official journal of the Japanese Cancer Association
wileyonlinelibrary.com/journal/cas
Editor-in-Chief
Yusuke Nakamura
(The University of Chicago)
© 2016 Japanese Cancer Association
wileyonlinelibrary.com/journal/cas
The Japanese Cancer Association (JCA) is
an organization of researchers who carry
out basic and clinical cancer research.
JCA currently consists of approximately
16,000 members, and the areas that they
are specialized in are wide-ranging. JCA
functions as a forum where researchers with
diverse specialties, including life and medical
sciences, cancer therapeutics, bioinformatics,
and development of drugs and medical
equipment, gather via the keyword “cancer”
and exchange information.
The major activities of JCA include the
holding of “the Annual Meeting” and the
publication of “Cancer Science”. The Annual
Meeting is held once a year in autumn, and
approximately 5,000 researchers and students
regularly participate each year.
JCA has been enthusiastically promoting
the globalization of the association, and is
working positively to that by, for example,
holding International Sessions at the Annual
Meeting by inviting speakers from abroad,
especially from neighboring Asian countries
since 2008. JCA also started to provide travel
grants for researchers from neighboring Asian
countries to support their participation in the
Annual Meetings.
Cancer Science is the official journal of
JCA. Cancer Science succeeded the journal
GANN (cancer in Japanese), one of the
oldest cancer journals in the world, having
been founded in 1907, and has now served
as drivers of global cancer research for not
less than 100 years. Cancer Science is an
open access journal from 2014. Publication
of the journal is currently carried out under
the direction of Yusuke Nakamura (Editor
in Chief) and strong level of the articles
published received high acclaim across the
world.
JCA wants to carry on contributing to the
development of life sciences, promoting
the development of new cancer prevention
and treatment methods, and contributing
to society through the future promotion of
cancer research.
Yokohama, Oct 2016
03